Fluorescent Reporters and Biosensors for Probing the Dynamic Behavior of Protein Kinases
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Sensors 2010, 10, 6796-6820; Doi:10.3390/S100706796 OPEN ACCESS Sensors ISSN 1424-8220
Sensors 2010, 10, 6796-6820; doi:10.3390/s100706796 OPEN ACCESS sensors ISSN 1424-8220 www.mdpi.com/journal/sensors Review Intelligent Chiral Sensing Based on Supramolecular and Interfacial Concepts Katsuhiko Ariga 1,2,*, Gary J. Richards 1, Shinsuke Ishihara 1, Hironori Izawa 1,2 and Jonathan P. Hill 1,2 1 World Premier International (WPI) Research Center for Materials Nanoarchitectonics (MANA), National Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba 305-0044, Japan 2 Japan Science and Technology Agency, CREST, 1-1 Namiki, Tsukuba 305-0044, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +81-29-860-4597; Fax: +81-29-860-4832. Received: 17 June 2010; in revised form: 7 July 2010 / Accepted: 8 July 2010 / Published: 13 July 2010 Abstract: Of the known intelligently-operating systems, the majority can undoubtedly be classed as being of biological origin. One of the notable differences between biological and artificial systems is the important fact that biological materials consist mostly of chiral molecules. While most biochemical processes routinely discriminate chiral molecules, differentiation between chiral molecules in artificial systems is currently one of the challenging subjects in the field of molecular recognition. Therefore, one of the important challenges for intelligent man-made sensors is to prepare a sensing system that can discriminate chiral molecules. Because intermolecular interactions and detection at surfaces are respectively parts of supramolecular chemistry -
Supplementary Figure S1. Intracellular Ca2+ Levels Following Decursin Treatment in F11 Cells in the Presence of Menthol
Supplementary Figure S1. Intracellular Ca2+ levels following decursin treatment in F11 cells in the presence of menthol (A) Intracellular Ca2+ levels after treatment with decursin every 3 s. The red arrow indicates the duration of treatment with 200 μM of menthol and decursin. NC: The negative control treated with DMSO only; PC: The positive control treated with 200 μM menthol without decursin. (B) Average intracellular Ca2+ levels after treatment with decursin. The average was quantified from the normalized Δ340/380 ratio for 10 cycles after treatment with the decursin solution at the 10th cycle, as shown in Fig. 1A. The normalized Δ340/380 ratio was calculated using the following for- mula: [ratio of fluorescence intensity at 510 nm (emission) to that at 340 nm (excitation)]/[ratio of fluorescence intensity at 510 nm (emission) to that at a wavelength of 380 nm (excitation)]. Cells 2021, 10, 547. https://doi.org/10.3390/cells10030547 www.mdpi.com/journal/cells Cells 2021, 10, 547 2 of 5 Table S1. List of protein targets of decursin detected by the SwissTargetPrediction web tool Common Target Uniprot ID ChEMBL ID Target Class Probability name Poly [ADP-ribose] polymerase-1 PARP1 P09874 CHEMBL3105 Enzyme 0.104671941 N-acylsphingosine-amidohydro- NAAA Q02083 CHEMBL4349 Enzyme 0.104671941 lase Acid ceramidase ASAH1 Q13510 CHEMBL5463 Enzyme 0.104671941 Family A G protein- Neuropeptide Y receptor type 5 NPY5R Q15761 CHEMBL4561 0.104671941 coupled receptor Family A G protein- Melatonin receptor 1A MTNR1A P48039 CHEMBL1945 0.104671941 coupled -
Biosensor Laboratory Selected Publications 1. Irina Sorokulova
Biosensor Laboratory Selected Publications 1. Irina Sorokulova, Eric Olsen, Vitaly Vodyanoy, Bacteriophage biosensors for antibiotic resistant bacteria. Expert Rev Med Devices. 2014 Mar;11(2):175-86. doi: 10.1586/17434440.2014.882767. 2. I.Sorokulova, R. Guntupalli, E. Olsen, L. Globa, O. Pustovyy, V. Vodyanoy. Lytic Phage in Biosensing, ECS Transactions, 58 (23) 1-7 (2014) 10.1149/05823.000lecst ©The Electrochemical Society. 3. Jia, H, Pustovyy, OM, Waggoner, P, Beyers, RJ, Schumacher, J, Wildey, C, Barrett, J, Morrison, E, Salibi, N, Denney, TS, Vodyanoy, VJ, Deshpande, G. Functional MRI of the olfactory system in conscious dogs. PLoS One, 9:e86362 (2014). 4. Kyathanahally SP, Jia H, Pustovyy OM, Waggoner P, Beyers R, Schumacher J, Barrett J, Morrison EE, Salibi N, Denney TS, Vodyanoy VJ, Deshpande G. 2014. Anterior- posterior dissociation of the default mode network in dogs. Brain structure & function: 1- 14. 5. Moore T, Globa L, Barbaree J., Vodyanoy V., Sorokulova I. Antagonistic Activity of Bacillus Bacteria against Food-Borne Pathogens. Journal of Probiotics and Health. Vol. 1(3): 1-6 (2013) 6. Vitaly J. Vodyanoy, Yuri Mnyukh, The Physical Nature of "Giant" Magnetocaloric and Electrocaloric Effects, American Journal of Materials Science, Vol. 3 No. 5, 2013, pp. 105-109. doi: 10.5923/j.materials.20130305.01. 7. Moore T, Sorokulova I, Pustovyy O, Globa L, Vodyanoy V (2013). Microscopic evaluation of vesicles shed by rat erythrocytes at elevated temperatures. Journal of Thermal Biology, 38:487-492. 8. Moore T, Sorokulova I, Pustovyy O, Globa L, Pascoe D, Rudisill M, Vodyanoy V. (2013) Microscopic evaluation of vesicles shed by erythrocytes at elevated temperatures. -
Profiling Data
Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8 -
PIM2-Mediated Phosphorylation of Hexokinase 2 Is Critical for Tumor Growth and Paclitaxel Resistance in Breast Cancer
Oncogene (2018) 37:5997–6009 https://doi.org/10.1038/s41388-018-0386-x ARTICLE PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer 1 1 1 1 1 2 2 3 Tingting Yang ● Chune Ren ● Pengyun Qiao ● Xue Han ● Li Wang ● Shijun Lv ● Yonghong Sun ● Zhijun Liu ● 3 1 Yu Du ● Zhenhai Yu Received: 3 December 2017 / Revised: 30 May 2018 / Accepted: 31 May 2018 / Published online: 9 July 2018 © The Author(s) 2018. This article is published with open access Abstract Hexokinase-II (HK2) is a key enzyme involved in glycolysis, which is required for breast cancer progression. However, the underlying post-translational mechanisms of HK2 activity are poorly understood. Here, we showed that Proviral Insertion in Murine Lymphomas 2 (PIM2) directly bound to HK2 and phosphorylated HK2 on Thr473. Biochemical analyses demonstrated that phosphorylated HK2 Thr473 promoted its protein stability through the chaperone-mediated autophagy (CMA) pathway, and the levels of PIM2 and pThr473-HK2 proteins were positively correlated with each other in human breast cancer. Furthermore, phosphorylation of HK2 on Thr473 increased HK2 enzyme activity and glycolysis, and 1234567890();,: 1234567890();,: enhanced glucose starvation-induced autophagy. As a result, phosphorylated HK2 Thr473 promoted breast cancer cell growth in vitro and in vivo. Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo. Taken together, our findings indicated that PIM2 was a novel regulator of HK2, and suggested a new strategy to treat breast cancer. Introduction ATP molecules. -
Supramolecular Aggregates As Sensory Ensembles
ChemComm View Article Online FEATURE ARTICLE View Journal | View Issue Supramolecular aggregates as sensory ensembles Cite this: Chem. Commun., 2016, Qian Wang,* Zhao Li, Dan-Dan Tao, Qian Zhang, Peng Zhang, Dai-Ping Guo and 52, 12929 Yun-Bao Jiang* As a new emerging area in chemical sensing, sensing using supramolecular aggregates exhibits unique advantages over that using conventional small-molecule chemical sensors, in terms of high sensitivity Received 22nd July 2016, and selectivity, and the simplicity of the sensory building blocks. This Feature Article outlines the recent Accepted 31st August 2016 research progress made in sensing based on induced supramolecular aggregation–disaggregation. The DOI: 10.1039/c6cc06075g reviewed sensory building blocks, in general, in the form of a small molecular sensor, yet with a much simpler structure, which form aggregates, are those of perylene derivatives, pyrene derivatives, tetra- www.rsc.org/chemcomm phenylethylene derivatives, metallophilic species and metal–organic frameworks. Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Introduction in which four amino acid binding sites are covalently linked withinthesameEDTAframework,andthespecificbio- A molecular chemosensor in general consists of a molecular recognition which relies on multiple weak and less selective recognition site and a signal reporting group, which are either interactions operating in a cooperative manner, sensing using directly connected or linked by a spacer.1 In order to achieve aggregates that hold a more simply designed chemosensor(s) by high sensing performance, for instance, high sensitivity and noncovalent interactions was developed.2 Here the chemosensor- selectivity, the sensory molecule needs to be sophisticatedly like building block itself may exhibit less effective performance designed. -
Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene, -
Nanotechnology Publications: Leading Countries and Blocs
Date: January 29, 2010 Author Note: I provide links and a copy of my working paper (that you may make freely available on your website) and a link to the published paper. Link to working paper: http://www.cherry.gatech.edu/PUBS/09/STIP_AN.pdf Link to published paper: http://www.springerlink.com/content/ag2m127l6615w023/ Page 1 of 1 Program on Nanotechnology Research and Innovation System Assessment Georgia Institute of Technology Active Nanotechnology: What Can We Expect? A Perspective for Policy from Bibliographical and Bibliometric Analysis Vrishali Subramanian Program in Science, Technology and Innovation Policy School of Public Policy and Enterprise Innovation Institute Georgia Institute of Technology Atlanta, GA 30332‐0345, USA March 2009 Acknowledgements: This research was undertaken at the Project on Emerging Nanotechnologies (PEN) and at Georgia Tech with support by the Project on Emerging Nanotechnologies (PEN) and Center for Nanotechnology in Society at Arizona State University ( sponsored by the National Science Foundation Award No. 0531194). The findings contained in this paper are those of the author and do not necessarily reflect the views of Project on Emerging Nanotechnologies (PEN) or the National Science Foundation. For additional details, see http://cns.asu.edu (CNS‐ASU) and http://www.nanopolicy.gatech.edu (Georgia Tech Program on Nanotechnology Research and Innovation Systems Assessment).The author wishes to thank Dave Rejeski, Andrew Maynard, Mihail Roco, Philip Shapira, Jan Youtie and Alan Porter. Executive Summary Over the past few years, policymakers have grappled with the challenge of regulating nanotechnology, whose novelty, complexity and rapid commercialization has highlighted the discrepancies of science and technology oversight. -
Recent Advances in the Field of Bionanotechnology: an Insight Into Optoelectric Bacteriorhodopsin, Quantum Dots, and Noble Metal Nanoclusters
Sensors 2014, 14, 19731-19766; doi:10.3390/s141019731 OPEN ACCESS sensors ISSN 1424-8220 www.mdpi.com/journal/sensors Review Recent Advances in the Field of Bionanotechnology: An Insight into Optoelectric Bacteriorhodopsin, Quantum Dots, and Noble Metal Nanoclusters Christopher Knoblauch 1, Mark Griep 2 and Craig Friedrich 1,* 1 Department of Mechanical Engineering-Engineering Mechanics, Multi-Scale Technologies Institute, Michigan Technological University, 1400 Townsend Drive, Houghton, MI 49931, USA; E-Mail: [email protected] 2 U.S. Army Research Laboratory, Weapons and Materials Research Directorate, Aberdeen Proving Grounds, MD 21005, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-906-487-1922. External Editor: Yoke Khin Yap Received: 29 August 2014; in revised form: 8 October 2014 / Accepted: 15 October 2014 / Published: 22 October 2014 Abstract: Molecular sensors and molecular electronics are a major component of a recent research area known as bionanotechnology, which merges biology with nanotechnology. This new class of biosensors and bioelectronics has been a subject of intense research over the past decade and has found application in a wide variety of fields. The unique characteristics of these biomolecular transduction systems has been utilized in applications ranging from solar cells and single-electron transistors (SETs) to fluorescent sensors capable of sensitive and selective detection of a wide variety of targets, both organic and inorganic. This review will discuss three major systems in the area of molecular sensors and electronics and their application in unique technological innovations. Firstly, the synthesis of optoelectric bacteriorhodopsin (bR) and its application in the field of molecular sensors and electronics will be discussed. -
Emerging Roles for the Non-Canonical Ikks in Cancer
Oncogene (2011) 30, 631–641 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc REVIEW Emerging roles for the non-canonical IKKs in cancer RR Shen1 and WC Hahn1,2 1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA and 2Broad Institute of Harvard and MIT, Cambridge, MA, USA The IjB Kinase (IKK)-related kinases TBK1 and IKKe to form the mature p50 and p52 proteins. This have essential roles as regulators of innate immunity by processing is necessary for p50 and p52 to function as modulating interferon and NF-jB signaling. Recent work transcription factors (Dolcet et al., 2005). Distinct has also implicated these non-canonical IKKs in malignant NF-kB complexes are formed from combinations of transformation. IKKe is amplified in B30% of breast homo- and heterodimers of these family members cancers and transforms cells through the activation of (Bonizzi and Karin, 2004). NF-kB complexes are NF-jB. TBK1 participates in RalB-mediated inflamma- retained in the cytoplasm by a family of NF-kB-binding tory responses and cell survival, and is essential for the proteins known as the inhibitors of NF-kB(IkBs). survival of non-small cell lung cancers driven by oncogenic A variety of inflammatory stimulants initiate the KRAS. The delineation of target substrates and down- induction of NF-kB and trigger activation of the IkB stream activities for TBK1 and IKKe has begun to define Kinase (IKK) complex, which is composed of the their role(s) in promoting tumorigenesis. In this review, we catalytic kinases IKKa and IKKb, and the regulatory will highlight the mechanisms by which IKKe and TBK1 NF-kB essential modifier (NEMO, or IKKg) (Perkins, orchestrate pathways involved in inflammation and cancer. -
Design and Synthesis of Fluorescence-Based Siderophore Sensor Molecules for Feiii Ion Determination*
Pure Appl. Chem., Vol. 82, No. 11, pp. 2199–2216, 2010. doi:10.1351/PAC-CON-10-02-05 © 2010 IUPAC, Publication date (Web): 19 August 2010 Design and synthesis of fluorescence-based siderophore sensor molecules for FeIII ion determination* Bao-Lian Su1,2,‡, Nicolas Moniotte2, Noan Nivarlet2, Ge Tian2, and Jonathan Desmet2 1State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology, 122 Hongshan Luoshi Road, 430070 Wuhan, China; 2Laboratory of Inorganic Materials Chemistry, The University of Namur (FUNDP), 61 rue de Bruxelles, B-5000, Namur, Belgium Abstract: The design principles of fluorescence-based siderophore sensor molecules for detection of heavy transition-metal (HTM) ions are first reviewed. As an example, fluores- cein-desferrioxamine (FlDFO), a highly efficient fluorophore molecule combining a specific Fe ion receptor and a fluorescence-sensitive signalling site has been designed, synthesized, and used for dosing with Fe ions. Its response test shows its high selectivity and sensitivity to FeIII ions and its potential for nanobiosensor design. This work clearly identified that among two FlDFO positional isomers differing by the attachment of DFO at the 5- or 6-posi- tion of the bottom benzene ring of Fl, the fluorescence of 6-FlDFO is insensitive to the com- plexation with Fe ions. This is independent of the linkage used between Fl and DFO. Only 5-FlDFO could be a highly potential sensor molecule since it has been revealed that in a free state without complexation with Fe ions, this fluoroionophore sensor molecule gave a maxi- mum fluorescent signal. With successive Fe ion complexing, the fluorescence of 5-FlDFO decreased very sensitively and proportionally with ion concentration. -
Acute Myeloid Leukemia Antibodies
Acute Myeloid Leukemia Antibodies Catalog No. Product Name Applications Reactivity H00000207-M03 AKT1 monoclonal antibody (M03) WB, IHC, IF, IP, ELISA Human H00000208-M01 AKT2 monoclonal antibody (M01) WB, IF, ELISA Human H00010000-M02 AKT3 monoclonal antibody (M02) WB, IF, ELISA Human PAB14689 GRB2 polyclonal antibody WB Human H00006199-M08 RPS6KB2 monoclonal antibody (M08) WB, IF, ELISA Human H00000369-M05 ARAF monoclonal antibody (M05) WB, ELISA, PLA Human H00000572-M02 BAD monoclonal antibody (M02) WB, ELISA, PLA Human H00000673-M01A BRAF monoclonal antibody (M01A) WB, ELISA Human H00008900-M02 CCNA1 monoclonal antibody (M02) WB, ELISA, PLA Human MAB15125 CCND1 monoclonal antibody WB, IHC Human H00001050-B01P CEBPA purified MaxPab mouse polyclonal antibody (B01P) WB Human H00001147-M04 CHUK monoclonal antibody (M04) WB, IHC, IF, ELISA, PLA Human H00001978-M01 EIF4EBP1 monoclonal antibody (M01) WB, ELISA, PLA Human H00002322-M01A FLT3 monoclonal antibody (M01A) ELISA Human MAB3617 HRAS monoclonal antibody WB Human H00003551-B01P IKBKB purified MaxPab mouse polyclonal antibody (B01P) WB Human Acute Myeloid Leukemia Antibodies H00008517-M01 IKBKG monoclonal antibody (M01) WB, IHC, IF, ELISA, PLA Human H00003728-M01 JUP monoclonal antibody (M01) WB, IHC, IF, ELISA Human H00003815-M07 KIT monoclonal antibody (M07) WB, IHC, ELISA Human H00003845-M01 KRAS monoclonal antibody (M01) WB, IF, ELISA Human H00051176-M03 LEF1 monoclonal antibody (M03) WB, IF, ELISA Human H00005604-M01 MAP2K1 monoclonal antibody (M01) WB, ELISA Human H00005605-M11 MAP2K2 monoclonal antibody (M11) WB, IF, ELISA Human H00005594-M01 MAPK1 monoclonal antibody (M01) WB, IF, ELISA, PLA Human H00005595-M01 MAPK3 monoclonal antibody (M01) WB, IHC, IF, IP, ELISA Human Abnova H00000207-M03 H00003815-M07 H00005914-M03 AKT1 Mab (M03) staining of human stomach KIT Mab (M07) staining of human stomach RARA Mab (M03) staining of human carcinoma esophagus Abnova Corporation 9F, No.